Fourth Annual
Cancer Biologics
Approaches Changing the Treatment of Cancer
Day 1 | Day 2 | Day 3
Thursday, February 14
7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee
8:00 - 9:40 Plenary Keynote Panel: Emerging Technologies & Industry Perspectives
This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included. - Read more
Sponsored by
9:40 Refreshment Break in the Exhibit Hall with Poster Viewing
10:40 Chairperson's Remarks
Alison Betts, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism (PDM), Pfizer Worldwide Research & Development
10:45 Anti-Müllerian Inhibiting Substance Type II Receptor Antibodies for Ovarian Cancer Therapy
Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center
Antibodies with agonistic activity have been difficult to develop. Our efforts at isolating anti-MISIIR antibodies by phage display and using homology modeling to rationally design antibodies capable of binding to the highly conserved ligand binding site will be presented.
11:15 Improvements to ADC Safety with Calicheamicin
Puja Sapra, Ph.D., Director, Oncology Research Unit, Pfizer, Inc.
The ADC modality and its components, essential aspects of tumor cell biology and their impact on pharmacology and safety of ADC's will be discussed, with particular focus on clinical dose fractionation studies conducted with two calicheamicin conjugates in the clinic.
11:45 Clinical Development of a Novel Auristatin E-Based Antibody Drug Conjugate against SLC44A4 in Resistant Prostate Cancer
Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc.
ASG-5ME is a fully human antibody against SLC44A4 (expressed in 95% of prostate tumors) conjugated to monomethyl auristatin E.Phase I study will be discussed including challenges defining proof of concept in light of evolving standards of care.
12:15 pm Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
1:40 Chairperson's Remarks
Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc.
1:45 Predictive Drug Discovery for Novel Cancer Biologics
John Hunter, Ph.D., Vice President, Antibody Research & Development, Compugen, Inc.
Compugen has applied its Predictive Discovery platform to identify novel members of the B7/CD28 family for targeted antibody immunotherapy in cancer.Validation data for representative targets will be presented.
2:15 Function-Orientated Screening Strategies to Identify Novel and More Effective Cancer Therapeutics
Mary Haak-Frendscho, Ph.D., CEO, Igenica, Inc.
I will highlight Igenica's two innovative technology platforms, sTAg (surface-tagged tumor antigen profiling) and iTAb (in vivo anti-tumor antibody screening) that collectively offer function-orientated strategies to identify novel tumor antigens and effective antibody-based therapeutic candidates.
2:45 Proteomics for Trans-Membrane Targets for ADCs
John Terrett, Ph.D., CSO, Oxford Biotherapeutics, Inc.
Proteins with high expression on cancer plasma membranes are identified directly by mass spectrometric analysis of membranes from clinical samples. Targetability, prevalence, antigen density, and appropriate ADC development can be determined from a comprehensive proteomics database built at OBT.
3:15 Preclinical Development of MGA271, an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Claudia Fieger, Ph.D., Scientist, Protein Biochemistry, Macrogenics, Inc.
3:45 Valentine's Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance to View Posters)
4:30 Chairperson's Remarks
Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center
4:35 Understanding the Role of B Cells in Ovarian Cancer and Implications for Targeted Therapy
Nathalie Scholler, M.D., Ph.D., Assistant Professor, Obstetrics and Gynaecology, Gyn University of Pennsylvania
Anti-tumor effector T cells are inhibited by the tumor microenvironment. Recent experimental evidence demonstrates that B cell responses can regulate T cell functions in cancer patients, thus potentially enabling translational research with existing B cell-modifying drugs.
5:05 Adoptive Therapy of Cancer with Genetically Modified T Cells
Renier J. Brentjens, M.D., Ph.D., Associate Attending Physician, Associate Member, Department of Medicine, Memorial Sloan-Kettering Cancer Center
Production and clinical application of tumor targeted CAR T cells will be presented.Potential obstacles as well as approaches to address these limitations, including the use of IL-12 secreting T cells, will be discussed.
5:35 Allovectin®: In vivo Studies and Potential Synergy with Other Advanced Melanoma Immunotherapeutics
John Doukas, Ph.D., Senior Director, Pre-Clinical Safety and Efficacy, Vical, Inc.
Allovectin® is an immunotherapeutic currently completing evaluation in a pivotal Phase 3 study for metastatic melanoma. This presentation will review its proposed mechanisms of action and potential synergy with other immunotherapies, drawing supporting data from preclinical and clinical studies.
6:05 Sponsored Presentations (Opportunities Available)
6:35 Close of Day
Day 1 | Day 2 | Day 3